These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 1630589)

  • 21. Differential modulation of extracellular levels of 5-hydroxytryptamine in the rat frontal cortex by (R)- and (S)-zacopride.
    Barnes NM; Cheng CH; Costall B; Ge J; Naylor RJ
    Br J Pharmacol; 1992 Sep; 107(1):233-9. PubMed ID: 1384906
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Zacopride and BRL 24924 induce an increase in EEG-energy in rats.
    Boddeke HW; Kalkman HO
    Br J Pharmacol; 1990 Oct; 101(2):281-4. PubMed ID: 2257436
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of anxiolytic and anxiogenic drugs on exploratory activity in a simple model of anxiety in mice.
    Kilfoil T; Michel A; Montgomery D; Whiting RL
    Neuropharmacology; 1989 Sep; 28(9):901-5. PubMed ID: 2572995
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Zacopride: anxiolytic profile in rodent and primate models of anxiety.
    Costall B; Domeney AM; Gerrard PA; Kelly ME; Naylor RJ
    J Pharm Pharmacol; 1988 Apr; 40(4):302-5. PubMed ID: 2900320
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antagonists at the serotonin-3 receptor can reduce the fear-potentiated startle response in the rat: evidence for different types of anxiolytic activity?
    Nevins ME; Anthony EW
    J Pharmacol Exp Ther; 1994 Jan; 268(1):248-54. PubMed ID: 7905528
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Handling history of rats modifies behavioural effects of drugs in the elevated plus-maze test of anxiety.
    Andrews N; File SE
    Eur J Pharmacol; 1993 Apr; 235(1):109-12. PubMed ID: 8519271
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The interaction of R(+)- and S(-)-zacopride with PCPA to modify rodent aversive behaviour.
    Barnes NM; Costall B; Ge J; Kelly ME; Naylor RJ
    Eur J Pharmacol; 1992 Jul; 218(1):15-25. PubMed ID: 1356806
    [TBL] [Abstract][Full Text] [Related]  

  • 28. BRL 46470 potently antagonizes neural responses activated by 5-HT3 receptors.
    Newberry NR; Watkins CJ; Sprosen TS; Blackburn TP; Grahame-Smith DG; Leslie RA
    Neuropharmacology; 1993 Aug; 32(8):729-35. PubMed ID: 8413836
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effect of 5-HT3 receptor antagonists on the morphine-induced excitation of A10 dopamine cells: electrophysiological studies.
    Gifford AN; Wang RY
    Brain Res; 1994 Feb; 638(1-2):325-8. PubMed ID: 8199870
    [TBL] [Abstract][Full Text] [Related]  

  • 30. BRL 24924: a potent agonist at a non-classical 5-HT receptor positively coupled with adenylate cyclase in colliculi neurons.
    Dumuis A; Sebben M; Bockaert J
    Eur J Pharmacol; 1989 Mar; 162(2):381-4. PubMed ID: 2542062
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacological and endocrinological characterisation of stress-induced hyperthermia in singly housed mice using classical and candidate anxiolytics (LY314582, MPEP and NKP608).
    Spooren WP; Schoeffter P; Gasparini F; Kuhn R; Gentsch C
    Eur J Pharmacol; 2002 Jan; 435(2-3):161-70. PubMed ID: 11821022
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Behavioural effects in mice of subchronic buspirone, ondansetron and tianeptine. II. The elevated plus-maze.
    Rodgers RJ; Cutler MG; Jackson JE
    Pharmacol Biochem Behav; 1997 Feb; 56(2):295-303. PubMed ID: 9050088
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effect of the 5-HT3 receptor antagonist, RS-42358-197, in animal models of anxiety.
    Costall B; Domeney AM; Kelly ME; Tomkins DM; Naylor RJ; Wong EH; Smith WL; Whiting RL; Eglen RM
    Eur J Pharmacol; 1993 Mar; 234(1):91-9. PubMed ID: 8097165
    [TBL] [Abstract][Full Text] [Related]  

  • 34. KC 9172 (free base of KC 7218)--an antipsychotic/anxiolytic compound. I. Antipsychotic and anxiolytic activity in comparison with chlorpromazine, clozapine, diazepam and buspirone.
    Ruhland M; Krähling H; Fuchs A; Schön U
    Pharmacopsychiatry; 1988 Nov; 21(6):396-8. PubMed ID: 2907649
    [No Abstract]   [Full Text] [Related]  

  • 35. Central action of 5-HT3 receptor ligands in the regulation of sleep-wakefulness and raphe neuronal activity in the rat.
    Adrien J; Tissier MH; Lanfumey L; Haj-Dahmane S; Jolas T; Franc B; Hamon M
    Neuropharmacology; 1992 Jun; 31(6):519-29. PubMed ID: 1407392
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of the effects of buspirone and chlordiazepoxide on differential reinforcement of low rates of response.
    Panickar KS; McNaughton N
    Eur J Pharmacol; 1992 Jan; 210(3):307-13. PubMed ID: 1612104
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anxiolytic profile of girisopam and GYKI 52,322 (EGIS 6775). Comparison with chlordiazepoxide and buspirone.
    Horváth K; Andrási F; Botka P; Hámori T
    Acta Physiol Hung; 1992; 79(2):153-61. PubMed ID: 1363928
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Profile of action of 5-HT3 receptor antagonists, ondansetron and WAY 100289, in the elevated plus-maze test of anxiety of mice.
    Rodgers RJ; Cole JC; Tredwell JM
    Psychopharmacology (Berl); 1995 Feb; 117(3):306-12. PubMed ID: 7770606
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 5-HT3 receptor antagonists attenuate cocaine-induced locomotion in mice.
    Reith ME
    Eur J Pharmacol; 1990 Sep; 186(2-3):327-30. PubMed ID: 2289534
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Blockade of 5-HT-mediated enteric slow EPSPs by BRL 24924: gastrokinetic effects.
    Mawe GM; Branchek TA; Gershon MD
    Am J Physiol; 1989 Sep; 257(3 Pt 1):G386-96. PubMed ID: 2782410
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.